Dr. Chughtai discusses novel iTind system for BPH treatment
“The data is out to about 2 to 3 years now, so…[it’s] a little bit on the immature side, but it's very promising,” says Bilal Chughtai, MD.
In this video, Bilal Chughtai, MD, assesses the success of the iTind system as reported in the study, “Preservation of ejaculatory and erectile function with iTind system for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia,” presented recently at the 2021 American Urological Association annual meeting. Chughtai is an associate professor of urology, obstetrics and gynecology at Weill Cornell Medicine and an attending urologist at NewYork-Presbyterian Hospital, New York City, New York.
Academic, private practice urologists collaborate to change BPH reimbursement
April 1st 2024"We really aimed to affect 3 different contraindications and instead achieved retirement of the entire policy, which, we think, really opens up this wonderful technology to literally hundreds of thousands more patients across the country," says Arpeet Shah, MD.
